Dilated cardiomyopathy (DCM) is a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. This condition is characterized by enlargement of ventricular chamber, thinning of heart walls and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found to affect about 30% to 40% of the total DCM patients. Single gene mutations in either the structural proteins of the myocyte, such as dystrophin, metavinculin, and lamin, or of mitochondrial DNA are also a prominent cause of DCM. Other factors such as diabetes, thyroid disorder, alcoholism, viral infections of the heart and heart valve abnormalities can also lead to dilated cardiomyopathy. Moreover, according to the Pediatric Cardiomyopathy Registry, DCM occurs at a rate of 6 per million children. It is commonly diagnosed in younger children with an average age of diagnosis at 2 years
This 90 page report gives readers a comprehensive overview of the Dilated Cardiomyopathy Therapeutics Market. Browse through 5 data tables and 23 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
The growing prevalence of congestive heart failure is the only key factor that is driving the demand for dilated cardiomyopathy therapeutics; however, there are many factors that are expected to hamper the growth of this market in the forecast period. Easy availability of pacemakers, implantable cardioverter defibrillators, promising developments in gene therapy, and implantable devices such as heart pumps are the factors curbing the growth of the dilated cardiomyopathy therapeutics market. In addition, the various side effects associated with the use of dilated cardiomyopathy therapeutics and other easier therapies using devices that have negligible side effects will hold back the growth of this market in the next few years.
On the basis of drug class, the global market for dilated cardiomyopathy therapeutics has been classified into aldosterone antagonists, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. By pipeline drugs, the market has been segmented into ARRY-797, CAP-1002, MYDICAR, ixCELL-DCM, and OR-1. A detailed analysis of these segments has been presented in the research report.
The global dilated cardiomyopathy therapeutics market has been divided on the basis of geography into Europe, North America, Asia Pacific, and Rest of the World. In 2013, North America accounted for the largest share of the market owing to the growing adoption of branded drugs, and the rising occurrence of congestive heart failure. In the U.S., dilated cardiomyopathy strikes around five to eight people amongst every 100,000. Asia Pacific and the Rest of the World markets for dilated cardiomyopathy therapeutics are growing at a fast pace owing to the increasing per capita income, improving economic standards, and rising demand for generic drugs.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Dilated Cardiomyopathy Therapeutics Market by 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
Furthermore, the research report covers the competitive landscape of the global dilated cardiomyopathy therapeutics market including an overview of leading companies, their product portfolio, financial overview, business strategies, recent developments, and SWOT analysis. Some of the prominent players operating in the global market for dilated cardiomyopathy therapeutics are Novartis International AG, Celladon Corporation, Sanofi S.A., Vericel Corporation, AstraZeneca plc, Pfizer, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Janssen Pharmaceuticals, Inc., and Array BioPharma, Inc.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453